Clinical significance of mutations in DNA repair genes in patients with metastatic prostate cancer
Prostate cancer (PCa) is one of the most common malignant tumor in men. Significant advances have been made in the early detection and treatment of localized PCa, but metastatic castration-resistant PCa (mCRPC) remains one of the most challenging problems to treat in oncology. To improve treatment outcomes for patients at this stage of the disease, it is necessary to develop personalized therapy options based on the definition of biological predictors. In mCRPC, mutations in DNA repair genes are detected in ~23 % of patients with mCRPC. Detection of these mutations in patients with PCa has important clinical relevance. PCa with mutations in DNA repair genes may be sensitive to poly(ADP-ribose)-polymerase (PARP) inhibitors. Several studies II and III phase have demonstrated the effectiveness of PARP inhibitors with a high objective response rate in the treatment of mCRPC in patients with mutations in the DNA repair genes, which is definitely a more personalized approach to treatment. Identification of hereditary mutations in DNA repair genes is an important prognostic factor for the proband's relatives (for both men and women), which can later be used for genetic counseling of patients and the application of strategies to reduce the risk of malignant diseases..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Onkourologiâ - 17(2021), 1, Seite 82-88 |
| Sprache: |
Russisch |
|---|
| Beteiligte Personen: |
O. A. Mailyan [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Germline mutations |
|---|
| doi: |
10.17650/1726-9776-2021-17-1-82-88 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ030821649 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ030821649 | ||
| 003 | DE-627 | ||
| 005 | 20230502071251.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2021 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.17650/1726-9776-2021-17-1-82-88 |2 doi | |
| 035 | |a (DE-627)DOAJ030821649 | ||
| 035 | |a (DE-599)DOAJb0dfc8327cbb4b17aec2472ab89514c0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 0 | |a O. A. Mailyan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical significance of mutations in DNA repair genes in patients with metastatic prostate cancer |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Prostate cancer (PCa) is one of the most common malignant tumor in men. Significant advances have been made in the early detection and treatment of localized PCa, but metastatic castration-resistant PCa (mCRPC) remains one of the most challenging problems to treat in oncology. To improve treatment outcomes for patients at this stage of the disease, it is necessary to develop personalized therapy options based on the definition of biological predictors. In mCRPC, mutations in DNA repair genes are detected in ~23 % of patients with mCRPC. Detection of these mutations in patients with PCa has important clinical relevance. PCa with mutations in DNA repair genes may be sensitive to poly(ADP-ribose)-polymerase (PARP) inhibitors. Several studies II and III phase have demonstrated the effectiveness of PARP inhibitors with a high objective response rate in the treatment of mCRPC in patients with mutations in the DNA repair genes, which is definitely a more personalized approach to treatment. Identification of hereditary mutations in DNA repair genes is an important prognostic factor for the proband's relatives (for both men and women), which can later be used for genetic counseling of patients and the application of strategies to reduce the risk of malignant diseases. | ||
| 650 | 4 | |a prostate cancer | |
| 650 | 4 | |a metastatic castration-resistant prostate cancer | |
| 650 | 4 | |a mutations in dna repair genes | |
| 650 | 4 | |a parp inhibitor | |
| 650 | 4 | |a somatic mutations | |
| 650 | 4 | |a germline mutations | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a A. S. Kalpinskiy |e verfasserin |4 aut | |
| 700 | 0 | |a I. V. Reshetov |e verfasserin |4 aut | |
| 700 | 0 | |a K. M. Nyushko |e verfasserin |4 aut | |
| 700 | 0 | |a B. Ya. Alekseev |e verfasserin |4 aut | |
| 700 | 0 | |a S. P. Kokin |e verfasserin |4 aut | |
| 700 | 0 | |a V. A. Stakanov |e verfasserin |4 aut | |
| 700 | 0 | |a M. P. Golovashchenko |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Onkourologiâ |d ABV-press, 2015 |g 17(2021), 1, Seite 82-88 |w (DE-627)DOAJ00013029X |x 17269776 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2021 |g number:1 |g pages:82-88 |
| 856 | 4 | 0 | |u https://doi.org/10.17650/1726-9776-2021-17-1-82-88 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/b0dfc8327cbb4b17aec2472ab89514c0 |z kostenfrei |
| 856 | 4 | 0 | |u https://oncourology.abvpress.ru/oncur/article/view/1432 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1726-9776 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1996-1812 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2021 |e 1 |h 82-88 | ||